Skip to main content

Table 4 Multiple linear regression models of HbA 1c after combination therapy

From: Post-meal β-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibenclamide or acarbose

  Model 1 Model 2 Model 3
  β P β P β P
Drug group (0 = glibenclamide; 1 = acarbose) 0.089 0.410 0.152 0.127 0.145 0.126
Gender (0 = female; 1 = male) −0.163 0.110 - - - -
Age (years) −0.106 0.307 - - - -
Disease duration (years) 0.105 0.313 - - - -
BMI (kg/m2) 0.172 0.179 - - - -
HbA1c (%) 0.677 <0.001* 0.687 <0.001* 0.703 <0.001*
MISI 0.162 0.391 0.217 0.234 - -
HOMA-IR −0.305 0.080 −0.210 0.148 −0.244 0.085
HOMA-β (%) −0.030 0.864 0.029 0.835 - -
Insulinogenic index30 (pmol/mmol) −0.072 0.734 - - - -
AUCins120/AUCglu 120§(pmol/mmol) 0.301 0.258 0.302 0.150 0.158 0.249
DI120 −0.801 0.045* −0.743 0.031* −0.552 0.030*
DI30 0.456 0.226 0.329 0.176 0.284 0.142
  1. Multiple linear regression models with HbA1c after combination therapy as the dependent variable. All independent variables were collected before randomization of the second-line OADs.
  2. *P < 0.005; § total area under curve of insulin within 120 minutes divided by total area under curve of glucose within 120 minutes.
  3. DI, disposition index; HOMA-β, homeostasis model assessment β-cell function; HOMA-IR, homeostasis model assessment insulin resistance index;
  4. Incremental AUC, incremental area under curve during liquid mixed meal tolerance test; MISI, Matsuda insulin sensitivity index.